AlphaMol Science Ltd

AlphaMol Science Ltd is a GPCR Drug Discovery Innovator that leverages computational methods and cutting-edge biotechnology to accelerate pre-clinical GPCR drug discovery. The company has achieved remarkable milestones by inventing three first-in-class PCC within 3-9 months, a process that typically takes 5-7 years using traditional methods. G protein-coupled receptors (GPCRs) are pivotal drug targets, with approximately 40% of marketed drugs targeting GPCRs. AlphaMol has established a dedicated GPCR-purposed platform for drug discovery, showcasing its capabilities by outperforming Google's AlphaFold2 in the GPCR-DOCK 2021 global contest and securing the best outstanding award in the NVIDIA Inception contest for startups in 2022. The company's co-founders, Prof. Shuguang Yuan and Prof. Horst Vogel, have been recognized among the "top 2%" scientists globally. The Series A investment at 24 August 2023 was led by Shanghai Healthcare Capital, Huaqiang Capital, and New Value Capital, emphasizing the industry's recognition and support for AlphaMol's groundbreaking approach to GPCR drug discovery.